To investigate predictors of response, remission, low disease activity, damage, and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were treated with belimumab.

Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting

Orsolini, Giovanni;Rossini, Maurizio;
2020-01-01

Abstract

To investigate predictors of response, remission, low disease activity, damage, and drug discontinuation in patients with systemic lupus erythematosus (SLE) who were treated with belimumab.
2020
SLE, belimumab, rheumatology
File in questo prodotto:
File Dimensione Formato  
Early Disease and Low Baseline Damage as Predictors Gatto et al AR 2020.pdf

non disponibili

Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 422.23 kB
Formato Adobe PDF
422.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1019366
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 58
  • ???jsp.display-item.citation.isi??? 62
social impact